VOR
USDVor Biopharma Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$21.960
高値
$22.000
安値
$19.620
出来高
0.22M
企業ファンダメンタルズ
時価総額
140.9M
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
0.36M
取引所
NMS
通貨
USD
52週レンジ
関連ニュース
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Raises Price Target to $52
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma with a Buy and raises the price target from $3 to $52.
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to
Baird Upgrades Vor Biopharma to Outperform, Raises Price Target to $64
Baird analyst Jack Allen upgrades Vor Biopharma from Neutral to Outperform and raises the price target from $20 to $64.
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR
